JW Medical Systems

Singapore, 9 January 2008 ?

?Biosensors?) and Shangdong Weigao Group Medical Polymer Company Limited (Hong

Kong Stock Exchange: 8199, ?Weigao?) today announced that they have entered into

agreements for Biosensors to acquire an additional 30 percent interest in JW Medical

Systems Ltd. (?JW Medical?) and to grant Weigao an option to sell to Biosensors the

remaining 20 percent interest in JW Medical by 30 July 2009. The acquisition of the

further stake in JW Medical will enable Biosensors to establish a stronger presence in

China following its acquisition of the first 50 percent interest in JW Medical in

September 2007.

Yoh Chie Lu, Chairman and CEO of Biosensors said, ?This acquisition symbolizes a mutual

commitment between Biosensors and Weigao to forge stronger relationships as longterm

strategic partners in Asia. The demand for drug-eluting stents continues to grow

rapidly in China and having ownership of JW Medical will place us in a strong position to

create maximum traction in this important and large market. Additionally, with Weigao

now as a strategic shareholder of Biosensors, we will be able to leverage on its strength

to become a leader in Asia, particularly in China.?

?Since commercialization of its drug-eluting stent in early 2006, JW Medical has

demonstrated operational excellence and has successfully increased its production

capacity to meet rapidly growing demands. We can certainly leverage this experience as

we prepare ourselves for commercialization of our BioMatrix® drug-eluting stent. For

the nine months ended 30 September 2007, JW Medical reported an impressive net

profit of US$11.1 million which is about three times the net profit of US$3.8 million

earned in the initial nine months after commercialization of its drug-eluting stent. With

completion of the acquisition, we expect JW Medical not only to add sales to our top

line but also contribute positively to our profit line when its financial results are

consolidated with ours.? Mr. Lu added.

Mr. Lu further commented, ?Apart from the accretive impact of its financial results, JW

Medical can also augment our existing resources and expand our operational capability,

capacity, and distribution. Through JW Medical and Weigao, we are definitely better

able to introduce our future technologies into the China market and develop strategies

that can capitalize on the growth potential there.?

After the required approvals are obtained, Biosensors will issue 120 million of its

ordinary shares to Weigao in exchange for 30 percent of JW Medical. Biosensors will

issue another 40 million of its ordinary shares if Weigao exercises its option to sell the

remaining 20 percent of JW Medical to Biosensors.

Mr. Chen Xue Li, Chairman of Weigao group said, ?China certainly offers explosive

growth opportunities for companies with innovative technology and operational

excellence. As shareholders of Biosensors now, we can leverage on Biosensors?

leadership in interventional cardiology and enable Weigao to become a leader in the

medical device industry in Asia. At the same time, we can also work closely with

Biosensors and by utilizing our strengths in sales and marketing and knowledge of the

Chinese market we can bring Biosensors? new products and technology into the fastgrowing

market in China more effectively and efficiently. We look forward to becoming

a long-term shareholder and strategic partner of Biosensors to grow the business

beyond China as well.?

Under the agreement, Weigao also has the right to purchase up to 20 million additional

new ordinary shares in cash, at a price to be negotiated, within 60 days from the date of

the agreement. Weigao will own approximately 14.6 percent of the total outstanding

shares of Biosensors assuming the issuance of an aggregate 160 million ordinary shares

upon completion of the acquisition of the remaining 50 percent equity interest of JW

Medical and the further purchase of 20 million new shares by Weigao.

Mr. Lu further commented, ?I am very pleased that execution of these agreements will

have two positive impacts on Biosensors. First, we will quickly establish ourselves in

China through the ownership of a high-quality company such as JW Medical. Second, in

this process, we have managed to develop a stronger alliance with Weigao, a highlyreputable

company that can together with us, leverage on mutual strengths to create

greater shareholder value for both companies.?

Biosensors has submitted statutory filings related to this acquisition to the Singapore

Exchange and which are also available at Biosensors? corporate website atBiosensors International Group, Ltd. (Bloomberg: BIG SP,

www.biosensors.com under the Investor Relations section.

JW Medical Systems